This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

FDA Approves Daiichi Sankyo's NOAC

Saturday, January 10, 2015

Submitted by


Crystal Phend

The FDA recently approved the fourth new oral anticoagulant, Savaysa for use in non-valvular afib, DVT, and PE.  It is another factor Xa inhibitor.  Use in non-valvular afib requires renal function assessment prior to prescribing, as the drug is renally excreted.  Paradoxically, efficacy may be reduced in patients with better-than-normal renal function.

Add comment

Log in or register to post comments